孟鲁司特联合西替利嗪治疗难治性慢性荨麻疹的疗效观察

Montelukast combined with cetirizine in the treatment of refractory urticaria:a clinical observation

目的:评价孟鲁司特联合西替利嗪治疗难治性慢性荨麻疹的疗效和安全性。方法:采用随机、平行对照的临床试验,试验组47例采用孟鲁司特联合西替利嗪;对照组45例采用雷公藤多苷联合西替利嗪,共92例患者。在基线和随访2周、4周时对风团和瘙痒的积分进行评价并记录不良事件。结果:用药4周后试验组和对照组的有效率分别为57.45%和60%,两组差异无统计学意义。试验组和对照组的不良事件发生率分别为8.51%和11.11%,差异无统计学意义。结论:孟鲁司特联合西替利嗪治疗难治性慢性荨麻疹疗效显著,安全性高。

Objective： To evaluate the clinical efficacy and safety of montelukast combined with cetirizine in the treatment of refractory urticaria. Method： A randomized and controlled clinical trial was conducted. A total of 92 patients with refractory urticaria were randomly divided into the treatment group with montelukast combined with cetirizine, and the control group with Tripterygium glycoside combined with cetirizine. Total symptom scores were calculated for the patients at the baseline, week 2 and 4 during the treatment based on the individual scores for wheal and prutitus, and the incidene of adverse events was recorded. Results： Ninety-two patients completed the trial, including 45 patients in the treatment group and 47 patients in the control group. After 4 weeks of treatment, there was no significant difference in the response rate （57.45% vs. 60%, P 〈 0.05） and the incidence of adverse events （8.51% vs. 11.11%, P〈 0.05） between the two groups. Conclusion： Mentelukast combined with cetirizine in the treatment of refractory urticaria displays marked efficacy and high safety.